Results 231 to 240 of about 67,431 (260)

Imatinib mesylate

American Journal of Health-System Pharmacy, 2001
openaire   +2 more sources

Imatinib

Reactions Weekly, 2013
  +5 more sources

A phase I–II study of everolimus (RAD001) in combination with imatinib in patients with imatinib-resistant gastrointestinal stromal tumors

Annals of Oncology, 2010
P Reichardt, Jean-Yves Blay, H Dumez
exaly  

Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study

Blood, 2009
Robrecht de Bock, Gregor Verhoef, P Zachee   +2 more
exaly  

Imatinib-ULS-lysozyme: A proximal tubular cell-targeted conjugate of imatinib for the treatment of renal diseases

Journal of Controlled Release, 2012
Wim E Hennink, Robbert J Kok
exaly  

Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia after failure of first-line imatinib: a randomized phase 2 trial

Blood, 2007
Hagop Kantarjian, Nelson Hamerschlak, Philippe Rousselot   +2 more
exaly  

Imatinib

Reactions Weekly, 2018
  +5 more sources

Imatinib

Reactions Weekly, 2008
  +4 more sources

Synergistic activity of imatinib and 17-AAG in imatinib-resistant CML cells overexpressing BCR-ABL – Inhibition of P-glycoprotein function by 17-AAG

Leukemia, 2005
J Topaly, Marlon R Veldwijk, Anna Jauch   +2 more
exaly  

Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial

Lancet, The, 2004
Jaap Verweij, Paolo G Casali, John Zalcberg   +2 more
exaly